ProjekttransMed – Educating the next generation of scientists in translational medicine: Focus on eye diseases
Grunddaten
Akronym:
transMed
Titel:
Educating the next generation of scientists in translational medicine: Focus on eye diseases
Laufzeit:
01.12.2017 bis 30.11.2021
Abstract / Kurz- beschreibung:
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 765441
Medicine today experiences a gap between basic research and successful clinical translation that delays establishment of urgently needed therapies. This is very clearly so in blinding retinal degenerations (RDs), where most are yet untreatable, even with a wealth of basic and pre-clinical research data available. To address this problem, transMed proposes an innovative programme to educate “translational researchers” that focuses on the bench-to-bedside development oftreatments for RD.
The transMed consortium joins four academic groups (EKUT, UNIMORE, ULUND, HI) with four non-academic and SME partners (SPPD, INCU, Oculis, PamGene), and five partner organisations (2BBB, BIOLOG, NLO, HCTC, EVI) with intersectoral collaborations already ongoing. Each transMed partner will contribute specific critical expertise to a curriculum covering all major aspects of translational research: From basic research into disease mechanisms and target definition, to drug design and development, in vitro test systems and in vivo disease models, drug delivery systems, biomarkers, good manufacturing practice, toxicological testing and pharmacokinetics, regulatory affairs, intellectual property, all the way to clinical trials and commercialisation.
Medicine today experiences a gap between basic research and successful clinical translation that delays establishment of urgently needed therapies. This is very clearly so in blinding retinal degenerations (RDs), where most are yet untreatable, even with a wealth of basic and pre-clinical research data available. To address this problem, transMed proposes an innovative programme to educate “translational researchers” that focuses on the bench-to-bedside development oftreatments for RD.
The transMed consortium joins four academic groups (EKUT, UNIMORE, ULUND, HI) with four non-academic and SME partners (SPPD, INCU, Oculis, PamGene), and five partner organisations (2BBB, BIOLOG, NLO, HCTC, EVI) with intersectoral collaborations already ongoing. Each transMed partner will contribute specific critical expertise to a curriculum covering all major aspects of translational research: From basic research into disease mechanisms and target definition, to drug design and development, in vitro test systems and in vivo disease models, drug delivery systems, biomarkers, good manufacturing practice, toxicological testing and pharmacokinetics, regulatory affairs, intellectual property, all the way to clinical trials and commercialisation.
Schlüsselwörter:
translationale Forschung
Retina
Netzhaut, retina
Retinitis pigmentosa
Netzhautentzündung, retinitis pigmentosa
gesteuerte Wirkstofffreisetzung
controlled drug releax
Beteiligte Mitarbeiter/innen
Leiter/innen
Forschungsinstitut für Augenheilkunde
Department für Augenheilkunde, Kliniken und klinische Institute, Medizinische Fakultät
Department für Augenheilkunde, Kliniken und klinische Institute, Medizinische Fakultät
Ansprechpartner/innen
Wheeler-Schilling, Thomas
Department für Augenheilkunde
Kliniken und klinische Institute, Medizinische Fakultät
Kliniken und klinische Institute, Medizinische Fakultät
Department für Augenheilkunde
Kliniken und klinische Institute, Medizinische Fakultät
Kliniken und klinische Institute, Medizinische Fakultät
Lokale Einrichtungen
Forschungsinstitut für Augenheilkunde
Department für Augenheilkunde
Kliniken und klinische Institute, Medizinische Fakultät
Kliniken und klinische Institute, Medizinische Fakultät
Geldgeber
Brüssel, Belgien